Incyte Corporation (Nasdaq:INCY) today announced that Jim Daly has joined Incyte as Executive Vice President and Chief Commercial Officer, reporting to Paul Friedman, M.D., Incyte's President and Chief Executive Officer. Formerly Senior Vice President, North America Commercial Operations at Amgen, Mr. Daly is joining Incyte effective today and will serve on the executive leadership team, assuming responsibility for Incyte’s commercial organization, including sales, marketing and business development.
“Jim brings extensive industry experience to Incyte having successfully launched and commercialized multiple products, notably in oncology,” stated Dr. Friedman. “His proven leadership skills and commitment to improving the lives of patients will be of great value to the ongoing commercialization of Jakafi in myelofibrosis, its potential expansion into other indications and the future advancement of our pipeline.”
“Jakafi is a novel, first-in-class product that is making a remarkable difference for patients with this debilitating condition,” stated Mr. Daly. “I’m excited by Incyte’s cutting-edge science and the potential commercial value of its substantial pipeline. Incyte’s leadership position in the development of oral JAK inhibitors to address unmet needs in a wide range of grievous illnesses represents a unique opportunity. I look forward to joining the team, building on its success with Jakafi and contributing to the development and commercialization of Incyte’s future products.”
Prior to joining Incyte, Mr. Daly held multiple leadership positions at Amgen, Inc. In his last role, Mr. Daly was Senior Vice President, responsible for North America Commercial Operations as well as Global Marketing and Commercial Development. From 2001 to 2005, he served as Vice President and General Manager of Amgen’s Oncology Business Unit. During his time at Amgen, his teams were responsible for the successful launch of many oncology products, including Aranesp®, Neulasta®, Vectibix®, Nplate® and, most recently, Xgeva®.Previously, Mr. Daly spent 17 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he advanced through numerous positions of increasing responsibility in the United States and abroad. Mr. Daly earned his undergraduate degree in Pharmacy and his Master’s degree in Business Administration from the State University of New York in Buffalo.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV